ArticleNature communications2024
Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- An integrated review of monkeypox: from pathogen and epidemiology to diagnostics, control, and challenges.Emerging microbes & infections · 2026Review
- Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model.Emerging microbes & infections · 2026Article
- Plant-based production and characterization of monoclonal antibodies targeting extracellular enveloped proteins of the Mpox Virus.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- Cross-protective human antibodies against the Mpox virus discovered through structure-guided screening.Cell discovery · 2026Article
- Current Strategies for Selecting Recombinant Orthopoxvirus Proteins for Immunobiological and Diagnostic Applications.Viruses · 2026Review
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- An experimentally validated structure-based computational framework for humanisation of anti-orthopoxvirus antibodies.EBioMedicine · 2026Article
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- Pathogenic signatures and therapeutic evaluation of emergent MPXV Clade Ib in low-susceptibility and immunocompromised mouse models.BMC microbiology · 2026Article
- Bruton's tyrosine kinase inhibitor BTKi-2 inhibits mpox virus and vaccinia virus infection.Virologica Sinica · 2026Article
- Article
- Structural basis of mpox virus A30/H2 subcomplex formation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Sero-genomic evidence for occult mpox exposure in healthy Nigerian adults.Nature communications · 2026Article
- Monkeypox Virus Countermeasures: Vaccines, Antibodies, Drugs and Traditional Chinese Medicine.Drug design, development and therapy · 2026Review
- Comparative humoral profiles in mpox cases, survivors, and vaccinated individuals reveal correlates of protection against MPXV.Cell reports. Medicine · 2025Article
- Potent neutralization by antibodies targeting the MPXV A28 protein.Nature communications · 2025Article
- Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments.Military Medical Research · 2025Review
- Anti-M1R/B6R antibody characterization and bispecific design for enhanced orthopoxvirus protection.EMBO molecular medicine · 2025Article
- Multivalent mpox protein nanoparticle vaccines confer cross-protection against orthopoxvirus infection.PLoS pathogens · 2025Article
- Bivalent single-domain antibodies show potent mpox virus neutralization through M1R antigen.Communications biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The recent outbreak of mpox epidemic, caused by monkeypox virus (MPXV), poses a new threat to global public health. Here, we initially assessed the preexisting antibody level to the MPXV B6 protein in vaccinia vaccinees born before the end of the immunization program and then identified two monoclonal antibodies (MAbs), hMB621 and hMB668, targeting distinct epitopes on B6, from one vaccinee. Binding assays demonstrate that both MAbs exhibit broad binding abilities to B6 and its orthologs in vaccinia (VACV), variola (VARV) and cowpox viruses (CPXV). Neutralizing assays reveal that the two MAbs showed potent neutralization against VACV. Animal experiments using a BALB/c female mouse model indicate that the two MAbs showed effective protection against VACV via intraperitoneal injection. Additionally, we determined the complex structure of B6 and hMB668, revealing the structural feature of B6 and the epitope of hMB668. Collectively, our study provides two promising antibody candidates for the treatment of orthopoxvirus infections, including mpox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.